Sohini Das

Tata Motors CV swings to ₹1,257 crore profit in Q2; revenue rises 36%

Commercial vehicle wholesales grow 42%; commodity costs weigh on margins

DHL bets on India growth, prefers organic expansion over acquisitions

Logistics major is willing to take higher investment risks in India, with pharmaceutical, electric vehicle and semiconductor supply chains expected to drive future demand

Bharat Biotech arm, VeGen Bio to manufacture advanced cancer treatment

Partnership expands vaccine maker's push into cell and gene therapies; companies target commercialisation of blood cancer treatment by 2028

Car inventory levels lower this festival season amid rising demand

The gap between car wholesales and retail registrations narrowed 45% Y-o-Y in September, as strong festive demand kept dealer inventories lower than last year despite increased dispatches.

Pharma haircare market in India finds its growth roots in young patients

Growth more than twice that of overall dermatology market; September sales surge 37.1% year-on-year, driven largely by higher volumes

Iveco Group shareholders approve Tata Motors' takeover proposals

Iveco shareholders approved key resolutions for Tata Motors' €3.91 billion acquisition, lowering the minimum share acceptance threshold from 95% to 80% and easing the path to completion.

Tyre makers ready for BS-VII abrasion norms, seek clarity on testing rules

Proposed tyre abrasion norms from April 2031 are expected to drive R&D investments as manufacturers seek clarity on testing protocols while grappling with rising raw material costs

Mini car sales jump 86% in H1 as entry-level segment shows recovery signs

Passenger vehicle wholesales rise 30.7% in Q2; heavy trucks and scooters lead growth in their respective segments

Mankind Pharma to acquire 70% in Belgian biotech firm for €48 million

Deal marks entry into next-generation CAR-T cancer therapies as company expands global innovation ambitions

BS-VII clock starts ticking as Centre sets 2029 target for emission norms

The government has proposed BS-VII emission norms from April 2029, introducing stricter real-world testing and brake and tyre pollution limits, while automakers seek more time to comply

Biocon inks patent settlement pact with Genentech for breast cancer drug

The deal allows Biocon to launch the biosimilar in the EU and the UK from the Q1 of 2027, and in the US from the Q3 of 2028

72% of students seeking mental healthcare report self-harm thoughts: Amaha

A study of 13,825 people found that 53 per cent had experienced mental health concerns for over a year before reaching the provider, highlighting barriers to timely care

Auto revenue seen rising up to 28% in Q2; input costs may squeeze margins

Q2 results preview: Volume-led sales growth may outpace profits

Luxury carmakers tap India's growing appetite for bespoke vehicles

From yacht-matched interiors to family crests, affluent buyers are personalising their set of wheels

Pharmacy margin cap may lead to tariff recalibration: Max Healthcare MD

Max Healthcare's Abhay Soi discusses the economics of hospital care, regulatory scrutiny of medicine mark-ups and reforms needed to improve affordability and expand healthcare capacity

In 2025, sub-₹10 lakh car market share fell to 52% from 80% in 2019

Sales in price band remain flat between 2019 and 2025 even as overall PV market grows 54%; nine in 10 used cars sell for ₹10 lakh or less

Electric PV sales nearly double in September; e-two-wheeler sales rise 89%

EV penetration in passenger vehicles rises to 8.5 per cent as electric two-wheeler sales climb 88.7 per cent and established manufacturers capture more market growth.

Auto dealers gear up for robust Oct as festival season bookings rise

Auto dealers expect deferred purchases to convert into festive deliveries from mid-October, while higher PV inventory and EV supply constraints remain key monitorables

Ayush eyes new frontiers: Insurance, hospitals may drive next growth phase

Insurance cover and hospitals could drive the next phase of expansion. But evidence-backed treatment will be key

GST Council may give export status to clinical trials for overseas sponsors

Proposals include ITC relief on free samples and expired drugs, while a 90% refund of accumulated credit could ease working-capital pressure for drugmakers